« Return to News | Drug Sponsors

Proteonomix licenses exclusive worldwide rights to novel anti-tumor technology

Thursday, August 23, 2012 10:19 AM

Proteonomix, a Hawthorne, N.J.-based biotechnology company focused therapeutics based upon the use of human cells and their derivatives, has entered into an exclusive worldwide license agreement for a novel source of primary human cells that secrete a factor capable of inhibiting tumor cell growth and causing tumor cell death.

The technology, developed by Ian McNiece, Ph.D., chief scientific officer of Proteonomix, consists of methods for isolation and propagation of the primary human cells, gene profiles obtained from the cells identifying candidate micro RNAs and growth factor genes, and methods for generating culture media conditioned by these cells for isolation of the inhibitory factor or factors.

“Recent experiments demonstrated the ability of these novel human cells and even the culture media conditioned by these cells to inhibit the proliferation of tumor cells, ultimately leading to their death,” said Steven Byle, chief technology officer of Proteonomix. “This technology has the potential to identify molecules that can kill tumor cells and provides insights into the potential delivery of these inhibitory factors in vivo.”

Terms of the license included an upfront license fee, an agreement with a related party and payments due upon achieving clinical and regulatory milestones based on success in developing products, as well as a royalty on sales of products resulting from this technology.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.